Comment on efficacy, safety, and tolerability of Lifitegrast 5% eye drops: A randomized, double-blind, active-controlled trial in Indian patients with dry eye disease.
作者信息
Srikanth Krishnagopal, Sridhanya V
机构信息
Department of Ophthalmology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth (Deemed to be University), Pillayarkuppam, Pondicherry, India.
出版信息
Indian J Ophthalmol. 2025 Jan 1;73(1):154. doi: 10.4103/IJO.IJO_2424_24. Epub 2024 Dec 23.
Abstract
摘要
相似文献
1
Comment on efficacy, safety, and tolerability of Lifitegrast 5% eye drops: A randomized, double-blind, active-controlled trial in Indian patients with dry eye disease.5% 利非司特滴眼液的疗效、安全性及耐受性评价：一项针对印度干眼症患者的随机、双盲、活性对照试验
Indian J Ophthalmol. 2025 Jan 1;73(1):154. doi: 10.4103/IJO.IJO_2424_24. Epub 2024 Dec 23.
2
Efficacy, safety, and tolerability of lifitegrast 5% eye drops: A randomized, double-blind, active-controlled trial in Indian patients with dry eye disease.5% 利非司特滴眼液的疗效、安全性及耐受性：一项针对印度干眼症患者的随机、双盲、活性对照试验。
Indian J Ophthalmol. 2025 Jan 1;73(1):88-94. doi: 10.4103/IJO.IJO_23_24. Epub 2024 Aug 14.
3
Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease.5.0% 利非司特滴眼液的安全性和耐受性：干眼疾病五项随机对照试验的汇总分析
Eur J Ophthalmol. 2019 Jul;29(4):394-401. doi: 10.1177/1120672118791936. Epub 2018 Aug 16.
4
Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).利福平格拉司特治疗干眼疾病的 III 期、随机、双盲、安慰剂对照试验（OPUS-3）结果。
Ophthalmology. 2017 Jan;124(1):53-60. doi: 10.1016/j.ophtha.2016.09.025. Epub 2016 Oct 27.
5
Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.5.0% 立他司特滴眼液在干眼症患者中的安全性：一项为期1年的多中心随机安慰剂对照研究。
Cornea. 2016 Jun;35(6):741-8. doi: 10.1097/ICO.0000000000000803.
6
Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.利福平眼科溶液 5.0%对比安慰剂治疗干眼疾病：随机 III 期 OPUS-2 研究结果。
Ophthalmology. 2015 Dec;122(12):2423-31. doi: 10.1016/j.ophtha.2015.08.001. Epub 2015 Sep 11.
7
Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.利福平眼科溶液 5.0%治疗干眼症：OPUS-1 期 3 研究结果。
Ophthalmology. 2014 Feb;121(2):475-83. doi: 10.1016/j.ophtha.2013.09.015. Epub 2013 Nov 26.
8
Lifitegrast: a novel drug for patients with dry eye disease.lifitegrast：一种用于干眼症患者的新型药物。
Ther Adv Ophthalmol. 2019 Aug 22;11:2515841419870366. doi: 10.1177/2515841419870366. eCollection 2019 Jan-Dec.
9
Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials.lifitegrast在三项随机对照试验中治疗干眼病体征和症状的临床疗效。
Curr Med Res Opin. 2016 Oct;32(10):1759-1765. doi: 10.1080/03007995.2016.1210107. Epub 2016 Jul 22.
10
Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Patients With Dry Eye Disease Associated With Ocular Graft-Versus-Host Disease.5% 利非司特滴眼液治疗与眼部移植物抗宿主病相关的干眼症患者的疗效和安全性
Cureus. 2024 Aug 8;16(8):e66437. doi: 10.7759/cureus.66437. eCollection 2024 Aug.
本文引用的文献
1
Efficacy, safety, and tolerability of lifitegrast 5% eye drops: A randomized, double-blind, active-controlled trial in Indian patients with dry eye disease.5% 利非司特滴眼液的疗效、安全性及耐受性：一项针对印度干眼症患者的随机、双盲、活性对照试验。
Indian J Ophthalmol. 2025 Jan 1;73(1):88-94. doi: 10.4103/IJO.IJO_23_24. Epub 2024 Aug 14.
2
Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.两项关于环孢素眼用乳剂治疗中重度干眼病疗效和安全性的多中心随机研究。环孢素3期研究组。
Ophthalmology. 2000 Apr;107(4):631-9. doi: 10.1016/s0161-6420(99)00176-1.
Zotero 插件